MULTIPLE MYELOMA

The FDA has granted a regenerative medicine advanced therapy designation to the allogeneic chimeric antigen receptor T-cell therapy ALLO-715 for the treatment of relapsed or refractory multiple myeloma,.

David Dingli, MD, PhD, discussed the case of a 51-year-old patients with transplant-eligible myeloma.

Rafael Fonseca, MD, reviews efficacy and safety data from the phase 3 MAIA trial and discusses their implications for clinical practice.

Rafael Fonseca, MD, discusses the role of monoclonal antibodies in the first-line setting in patients with newly diagnosed multiple myeloma.

Rafael Fonseca, MD, reviews first-line therapy options and considerations for treatment selection for patients with newly diagnosed multiple myeloma.

Rafael Fonseca, MD, discusses the challenges of treating patients with newly diagnosed multiple myeloma.

Rafael Fonseca, MD, reviews the case overview of a 77-year-old woman with multiple myeloma.

Rafael Fonseca, MD, discusses the case of a 77-year-old woman with multiple myeloma, treatment approach for patients with newly diagnosed multiple myeloma, and the trials providing insight into the treatment of this disease.

Ixazomib plus cyclophosphamide, and dexamethasone elicited higher rates of efficacy compared with ixazomib/dexamethasone, followed by single-agent ixazomib maintenance, in patients with transplant-ineligible newly diagnosed multiple myeloma/

Investigators reported an objective response rate of 73% for the anti–B-cell maturation antigen teclistamab in patients with relapsed/ refractory multiple myeloma, according to results from an ongoing study.

Adriana Rossi, MD, provides clinical pearls on the management of triple-class refractory multiple myeloma.

An expert in multiple myeloma shares her perspective on the significance of recent single-agent approvals for patients with triple-class refractory multiple myeloma and highlights promising combination regimens under investigation.

Dr Adrianna Rossi reviews considerations for treatment selection in the triple-class refractory setting in patients with multiple myeloma.

Adriana Rossi, MD, describes key clinical trials and their implications for the management of triple-class refractory multiple myeloma.

Dr Adriana Rossi reviews the therapeutic options for patients with triple-class refractory multiple myeloma in terms of mechanism of action and safety profile.

An expert in multiple myeloma provides insight on the treatment challenges for patients with triple-class refractory disease, particularly after fourth or later lines.

Adriana Rossi, MD, presents the case of a 75-year-old woman with triple-class refractory multiple myeloma.

Adriana Rossi, MD, describes the treatment approach in caring for a 75-year-old woman with triple-class refractory multiple myeloma [RRMM] while highlighting results from the relevant DREAMM and SOHO studies.

During a virtual Targeted Oncology Case-Based Roundtable event, Rafael Fonseca, MD, lead a discussion on how MRD status can guide treatment of multiple myeloma

Infection mortality rate were lower in patients with multiple myeloma who were coronavirus disease 2019 positive and received maintenance lenalidomide than those who did not receive lenalidomide, according to study results presented during the 2nd European Myeloma Network Meeting.

Robert Rifkin, MD, FACP, a hematology oncologist at the Rocky Mountain Cancer Centers, discusses the need for novel treatment options in the relapsed or refractory multiple myeloma population.

Jonathan L. Kaufman, MD, discusses current challenges and unmet needs in the treatment landscape and provides insight into potential improvements in the future of multiple myeloma.

Expert in the management of multiple myeloma Jonathan Kaufman, MD, reviews factors to consider when selecting a treatment regimen for patients with relapsed disease.

Jonathan L. Kaufman, MD, considers updates from the GRIFFIN trial, the MAIA trial, and the PEGASUS study and comments on factors to consider for daratumumab-containing induction regimens.

Key opinion leader in hematology Jonathan L. Kaufman, MD, discusses standard treatment options for newly diagnosed multiple myeloma in transplant and nontransplant treatment settings.